| Document Date: 2012-08-31 14:12:19
Open Document File Size: 626,85 KBShare Result on Facebook
City CONTRAINDICATIONS / Reference / / Company Human Experience / Janssen Pharmaceuticals Inc. / / Event FDA Phase / / IndustryTerm rubber tip cap / machinery / drug products / / MedicalCondition polyuria / Priapism / e.g. stroke / schizophrenia / Seizures / Leukopenia / Dysphagia / Carcinogenesis / Hyperglycemia / Neutropenia / Dyslipidemia / Stroke / extrapyramidal disorder / cerebrovascular disease / diabetes / Known hypersensitivity / chronic administration / transient ischemic attack / seizure / Syncope / Orthostatic Hypotension / Diabetes Mellitus / Parkinson’s Disease / Neuroleptic Malignant Syndrome / dizziness / drug-induced leukopenia/neutropenia / Tardive Dyskinesia / Agranulocytosis / Hyperprolactinemia / hypotension / akathisia / Dehydration / / Organization DOSAGE AND ADMINISTRATION / FDA / / / Position Major / / Product INVEGA / Extended-Release tablets / Extended-Release Tablet Injection / carbamazepine / GLUTEAL injection / risperidone / DELTOID injection / rifampin / Gluteal injections / INVEGA® SUSTENNA / / Technology Pharmacokinetics / Pharmacodynamics / / URL www.fda.gov/medwatch / /
SocialTag |
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use INVEGA® SUSTENNA® safely and effectively. See full prescribing information for INVEGA® SUSTENNA®. INVEGA® SUSTE